← All trials
NCT06929039
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2024
- Primary completion
- Oct 16, 2024
- Completion date
- Feb 25, 2025
- First posted
- Apr 15, 2025
- Last posted
- Apr 15, 2025
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kashiv BioSciences, LLCLead sponsor
- Kashiv BioSciences, LLCOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.